drugset / Trial / NCT05497778
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
Phase 1
Active not recruiting
19 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
To learn if adding a new medication, IM156, to treatment with gemcitabine and nab-paclitaxel is safe and tolerable. The ability of this combination to improve the success of this treatment for these patients will also be studied.
Timeline
- Start
- 2022-10-21
- Primary completion
- 2027-02-02
- Completion
- 2027-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | LIXUMISTAT | Small molecule | — | Oral |
| Subject | Nab-paclitaxel | Small molecule | — | Intravenous |